| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 14/05/2024 | 22:15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 11/01/2024 | 22:31 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 26/10/2023 | 22:05 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 04/10/2023 | 14:30 | GlobeNewswire Inc. | China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 31/07/2023 | 22:15 | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 19/05/2023 | 23:17 | Edgar (US Regulatory) | Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 10/05/2023 | 14:00 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 29/03/2023 | 20:20 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 29/03/2023 | 19:50 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 27/03/2023 | 12:02 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 28/02/2023 | 22:06 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 07/11/2022 | 14:00 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 18/07/2022 | 17:02 | Edgar (US Regulatory) | Annual and Transition Report (foreign Private Issuer) (20-f) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 18/05/2022 | 18:30 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 16/03/2022 | 13:01 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 15/03/2022 | 21:07 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 15/03/2022 | 03:33 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 20/01/2022 | 16:45 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 18/01/2022 | 12:47 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 14/01/2022 | 23:43 | GlobeNewswire Inc. | China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 14/01/2022 | 20:30 | PR Newswire (US) | China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 18/10/2021 | 14:00 | PR Newswire (US) | China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 19/02/2021 | 14:00 | PR Newswire (US) | China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 11/02/2021 | 12:08 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 09/09/2020 | 15:00 | PR Newswire (US) | NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 22/05/2020 | 21:50 | Edgar (US Regulatory) | Amended Report of Foreign Issuer (6-k/a) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 22/04/2020 | 22:38 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 16/03/2020 | 14:16 | PR Newswire (US) | China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 24/01/2020 | 20:23 | Business Wire | China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |
| 16/01/2020 | 14:00 | PR Newswire (US) | China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory | NASDAQ:SXTC | China SXT Pharmaceuticals Inc |